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Results: Overall, among SP isolates in AS and EU respec-
tively, S rates were 39.2 and 75.2% for PEN; 45.5 and 82.5%
for CFX; 21.1 and 67.4% for ERY; 19.3 and 75.6% for TET;
37.2 and 74.6% for SXT; and 98.0 and 98.8% for LFX. For all
countries combined the prevalence of MDR SP was 77.4% in
AS and 29.1% in EU. The most prevalent MDR phenotype in
AS was 5-drug R (including PEN, ERY, CFX, TET, and SXT) and
in EU it was 2-drug R (including ERY and TET). Among MDR
isolates, 97.4% in AS and 97.8% in EU were S to LFX. By coun-
try, the MDR rates (%) in EU were as follows: 42.7 FR; 37.9 IT;
37.2 SPN; 26.7 BG; 16.1 GE; and 9.4 UK. Comparatively, the
MDR rates in AS by region were dramatically higher (66.9%
HK, 76.7% SK, 85.6% CH, and 90.6% TW).
Conclusions: Decreased S among many commonly utilized
respiratory agents against SP, in particular beta-lactams and
macrolides, continues to be an issue in both EU and AS. How-
ever, SP remained >98% S to LFX in both regions. MDR rates
among SP is also a concern in AS (77%) and EU (29%), although
rates varied by country. Continued surveillance on a regional
basis is warranted to monitor changes in S among SP and to
help guide local empiric therapy.
doi:10.1016/j.ijid.2008.05.715
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Background: The Tigecycline In-Vitro Surveillance in Tai-
wan (TIST), initiated in 2006, is a nationwide surveillance
program designed to monitor longitudinally the in vitro
activities of tigecycline against commonly encountered
resistant bacteria in Taiwan. This study, part of TIST-2006
study, aims to compare the in vitro activities of tigecycline
against clinical isolates of Gram-positive bacteria.
Methods: A total of 805 isolates of Gram-positive bacte-
ria were collected from various sources of patients treated
at 20 teaching hospitals. Minimum inhibitory concentrations
(MICs) for tigecycline of these isolates were determined by
the broth microdilution methods according the guidelines
described by Clinical and Laboratory Standards Institute
(CLSI) and the E test as manufacturer’s description. Suscep-
tibility results of tigecycline were interpreted by the MIC
criteria provided by U.S. FDA. Agreement and error analysis
of results generated by two methods were also evaluated.
Results: Susceptibility results of tigecycline are summa-
rized in the table 1. Agreement of two methods was low:
70.8% for MRSA, 26.4% for S. pneumoiae, 20.5% for other
Streptococcus species, and 30.7% for VRE. There was no very
major or major error noted.
Conclusion: Tigecycline exhibited excellent in vitro activ-
ities against gram-positive cocci, including MRSA, VRE,
and penicillin-nonsusceptible S. pneumoiae (PNSSP) isolates
in Taiwan. Correlations between MIC values using broth
microdilution and the E test methods for these organisms
were poor.
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Background: There is evidence that hetero-resistance
may be associated with failure of vancomycin therapy. Most
routine MIC testing methods used in diagnostic laborato-
ries do not detect hVISA strains. There are few published
Canadian studies using other methods for this purpose.
Objective: To use the Macro E-test method and the Gly-
copeptide Resistance Detection (GRD) E-test (AB Biodisk,
Sweden)to assess the prevalence of hVISA among the bac-
teremic isolates of S. aureus at a tertiary care centre in
Canada.
Methods: Ninety two isolates of S. aureus including 7
Methicillin Resistant S. aureus (MRSA) from BSI were tested
by standard, Macro E-test and GRD methods. For the stan-
dard E-test, the organism was tested at 0.5 McFarland on
Mueller Hinton (MH)Agar, and incubated for 24 hours at 35 ◦C.
For Macro E-test, 100l of a 2.0 McFarland suspension was
used on BHI Agar incubated for 48 hours at 35 ◦C. For GRD,
0.5 McFarland inoculum was tested on MH with 5% blood,
incubated for 48 hours at 35 ◦C.A strain was deﬁned as hVISA
if it had an MIC of (>) 8g/ml for vancomycin and teicoplanin
by Macro or GRD E-test.
Results: All the isolates were sensitive to vancomycin
and teicoplanin, when tested by the standard method. The
MIC50 and MIC90 were: vancomycin 1.0g/ml and 1.5g/ml;
teicoplanin 0.5g/ml and 0.75g/ml. Though hVISA was
not detected among the 92 strains tested by Macro E-test
method as per the deﬁned criteria, some strains showed
increased MICs (6.0g/ml). MIC50 and MIC90 were: van-
comycin 3.0g/ml and 6.0g/ml; teicoplanin 3.0g/ml
and 6.0g/ml.The MIC50 and MIC90 by GRD were: van-
comycin 1.0g/ml and 1.5g/ml; teicoplanin 2.0g/ml and
3.0g/ml.
